465 related articles for article (PubMed ID: 28965781)
1. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Houston KA; King J; Li J; Jemal A
J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
[TBL] [Abstract][Full Text] [Related]
4. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
[TBL] [Abstract][Full Text] [Related]
5. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC
J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
Jemal A; Culp MB; Ma J; Islami F; Fedewa SA
J Natl Cancer Inst; 2021 Jan; 113(1):64-71. PubMed ID: 32432713
[TBL] [Abstract][Full Text] [Related]
7. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
8. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
9. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
10. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
11. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
12. Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012.
Hoffman RM; Meisner AL; Arap W; Barry M; Shah SK; Zeliadt SB; Wiggins CL
Cancer Epidemiol Biomarkers Prev; 2016 Feb; 25(2):259-63. PubMed ID: 26646364
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014.
Li J; Siegel DA; King JB
Ann Epidemiol; 2018 May; 28(5):328-330. PubMed ID: 29678312
[TBL] [Abstract][Full Text] [Related]
14. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
Shen X; Kumar P
J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266
[TBL] [Abstract][Full Text] [Related]
15. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
16. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
17. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
19. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
Dall'Era MA; deVere-White R; Rodriguez D; Cress R
Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
[TBL] [Abstract][Full Text] [Related]
20. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]